NCT06950034View on ClinicalTrials.gov

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

PHASE1RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia (CMML)Chronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2Refractory Chronic Myelomonocytic LeukemiaCMMLAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid LeukemiasRefractory Acute Myeloid Leukemia (AML)Acute Monocytic Leukemia
Interventions
BIOLOGICAL

STX-0712

STX-0712 is IV administered every 21 days until the patient discontinues treatment.

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

Solu Therapeutics, Inc

INDUSTRY